Idiopathic Inflammatory Myopathy (IIM) is an indication for drug development with over 30 pipeline drugs currently active. According to GlobalData, preregistered drugs for Idiopathic Inflammatory Myopathy (IIM) have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Idiopathic Inflammatory Myopathy (IIM) compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Idiopathic Inflammatory Myopathy (IIM) overview

Inflammation of muscle is known as inflammatory myopathy. If it is of unknown origin the condition is referred as idiopathic inflammatory myopathy. It is a group of autoimmune diseases characterized by inflammation resulting in organ dysfunction. Muscle weakness, joint pain and general tiredness (fatigue) are common symptoms. polymyositis, dermatomyositis, and sporadic inclusion body myositis are different forms of IIM. Genetic and environmental factors play a major role. Glucocorticoids remains as the first-line therapy for the IIMs with a standard prednisone dose of 1 mg/kg/day (high dose) to gain control of disease followed by a taper to the lowest possible dose to keep disease controlled and Intravenous immunoglobulin (IVIG) infusions and cyclophosphamide infusions.

For a complete picture of PTSR and LoA scores for drugs in Idiopathic Inflammatory Myopathy (IIM), buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.